Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +54.73%
#2 Pons Pons +49.77%
#3 StonkBroker StonkBroker +37.94%
#4 PondCoin PondCoin +37.35%
#5 TENDIES TENDIES +36.53%
#6 Magma Finance Magma Finance +34.48%
#7 Ocean Protocol Ocean Protocol +31.66%
#8 Official Trump Official Trump +27.66%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#10 Ore Ore +26.90%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Rank in Stocks #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Share Price
$0.07339369
Last synced: 2026-08-18
Market Cap
$25.24M
Change (1 day)
5.26%
Change (1 year)
-9.55%
Country
CA
Trade Resverlogix Corp. (RVX)

Category

Healthcare
Revenue for Resverlogix Corp. (RVX)
Revenue in Aug 2026 TTM: 0
According to Resverlogix Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Resverlogix Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH